Clinical Trials Logo

MDS clinical trials

View clinical trials related to MDS.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04109690 Withdrawn - MDS Clinical Trials

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

Start date: December 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed study is of a Liposomal formulation of cytarabine and daunorubicin (CPX-351) in patients treated for higher-risk myelodysplastic syndromes (MDS) experiencing hypomethylating agent failure.

NCT ID: NCT03138395 Withdrawn - Clinical trials for Myelodysplastic Syndromes

iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML

iCare3
Start date: September 15, 2017
Phase: N/A
Study type: Observational

This study will use droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma mutant allele frequency (MAF) in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR.

NCT ID: NCT02053545 Withdrawn - Lymphoma Clinical Trials

Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion

Start date: December 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Although a majority of children with leukemia and most hematological malignancies (Hodgkin's and Non-Hodgkin's lymphomas) can be cured with conventional chemotherapy, a subset of patients with resistant/recurrent high-risk disease are not cured with conventional treatment regimens. Investigators hypothesize that HSCT from a partially matched donor can be safe and effective for patients with very high risk hematologic malignancies when combined with post-transplant cyclophosphamide for prevention of graft-vs-host disease (GVHD).